Please login to the form below

cabozantinib

This page shows the latest cabozantinib news and features for those working in and with pharma, biotech and healthcare.

Merck’s Bavencio joins first-line kidney cancer face-off

Both combinations could challenge the position of Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab), which has started to replace Sutent and other TKIs like Exelixis’Cabometyx (cabozantinib) as the

Latest news

NICE clears Ipsen’s Cabometyx in first-line kidney cancer

access cabozantinib earlier in their treatment pathway.”.
Pfizer’s plans for Inlyta go awry with failed adjuvant trial

nivolumab) and Exelixis’multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).
FDA’s year-end approvals take annual tally to 46

Exelixis got the nod from the US regulator for Cabometyx (cabozantinib) as a first-line treatment for advanced renal cell carcinoma, giving the drug a boost against rival Sutent (sunitinib) from ... therapy. Analysts at Leerink have suggested the new
Ipsen’s liver cancer treatment clears phase III trial

Ipsen and partner Exelixis are on track to file cancer treatment Cabometyx (cabozantinib) for a new liver cancer indication in the first half of next year, following positive phase III trial ... Data showed cabozantinib provided a ‘statistically
NICE gives green light to Ipsen's Cabometyx

To date nearly 300 patients in the UK have benefited from cabozantinib through this Ipsen initiative, whilst the NICE process took place. ... We are delighted that now any eligible patient in the UK can benefit from cabozantinib.

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Accelerating innovation

Meanwhile, 2016 saw a licensing deal with Cabometyx (cabozantinib) from Californian biotech Exelixis and an agreement with 3B Pharmaceuticals to develop novel oncology radiopharmaceuticals. ... Focusing on the future. In terms of its new oncology products
Charting a course for expansion

Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.
Deal Watch March 2016

marketed product Cometriq (cabozantinib). ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?

CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma? ... Also, the secondary endpoint, response rate, was higher and more significant with cabozantinib.

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Senior Medical Writer: Competitive Salary

Senior Systematic Review Analyst - Oxford: Negotiable

Scientific Director / Editorial Team Leader: Great salary and benefits

New Business Director - PR: Competitive Salary and benefits

Medical/ Scientific Director: Salary TBC

Production Manager – Healthcare Communications: DOE

Associate Editorial Director – Med Comms – London: Salary TBC

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Medical Writers: Competitive Salary and Benefits

Associate Medical Director: Highly Competitive

Consultant Health Economics - London / Oxford: Negotiable

Account Director: Excellent benefits

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Senior Medical Writer: Great salary and benefits

Events Manager – Med Comms – Surrey: Salary TBC

Account Director: £48, 000 - £60, 000

Senior Account Director development role to Business Director, H...: Excellent package

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Associate Director, Market Access & HEOR – North-West: Negotiable

Consumer Health Account Director: Circa £60, 000 Gym and More

Senior Account Manager: Negotiable

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Quality in Care Diabetes 2018: the best in innovative diabetes care: Awards highlight new evidence-based approaches to improving care...